NeoFipronis (GS-441524) Package Insert and Dosage Information
NeoFipronis (Pronidesivir) GS-441524 is a groundbreaking oral medication specifically designed for the treatment of Feline Infectious Peritonitis (FIP). Approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, NeoFipronis is the first officially registered FIP treatment globally, offering a safe, non-invasive, and highly effective option for affected cats. This medication has demonstrated remarkable success in alleviating symptoms such as loss of appetite, lethargy, fever, ascites, pleural effusion, lymphadenopathy, granulomatous inflammation, neurological damage, and uveitis, which are characteristic of FIP.
Active Ingredient and Mechanism of Action
The active component of NeoFipronis is GS-441524, a potent nucleoside analog that inhibits coronavirus replication. Its antiviral efficacy has been validated through extensive research and clinical trials, confirming its ability to reduce viral loads rapidly and effectively. GS-441524 mimics natural nucleotides, disrupting the replication process of the FIP virus, leading to viral clearance and symptom improvement.
Administration and Dosage
NeoFipronis is administered orally based on the cat’s body weight. The standard dose is 15mg per kilogram of body weight, approximately half a tablet, once daily. For cats with neurological or ocular forms of FIP, the dosage should be increased under veterinary supervision to 30mg per kilogram daily. It is recommended to give the medication on an empty stomach—either one hour before feeding or two hours after—to enhance absorption. Consistency in dosing is essential for successful treatment outcomes.
Treatment Duration and Monitoring
A minimum of 12 weeks of continuous therapy is crucial. Missing doses can compromise treatment efficacy and should be avoided. During treatment, owners should monitor their cat’s appetite, temperature, activity levels, and overall behavior. Regular veterinary examinations, including blood tests and liver and kidney function assessments, are vital to ensure the medication’s safety and effectiveness. Adjustments to the dosage may be necessary based on clinical response and laboratory findings.
Safety and Precautions
Although NeoFipronis is classified as an over-the-counter medication, it is highly recommended to use it under the supervision of a licensed veterinarian. Proper veterinary guidance ensures correct dosing, minimizes risks, and optimizes treatment outcomes. NeoFipronis is intended solely for feline use; it is not safe for human consumption or administration to other species.
Quality Assurance and Purchase
To guarantee the authenticity and quality of NeoFipronis, purchase only from authorized sources. The official NeoFipronis website provides verified distributors and detailed product information. Avoid unauthorized sellers to prevent counterfeit products, which can jeopardize your cat’s health.
Conclusion
NeoFipronis (Pronidesivir) GS-441524 marks a significant advancement in feline medicine, offering a safe, effective, and easy-to-administer solution for cats suffering from FIP. Its rapid absorption, minimal side effects, and proven efficacy make it the preferred choice for veterinarians and pet owners alike. Early intervention and adherence to prescribed treatment protocols are critical to achieving complete recovery from FIP. Ensure your feline friend’s health by consulting a veterinarian and obtaining NeoFipronis through official channels.
